Supernus to Buy Navitor Pharmaceuticals Assets

Supernus Pharmaceuticals, Inc. has entered into an asset purchase agreement, effective April 1, 2026, to buy certain assets of Navitor Pharmaceuticals, Inc. and Navitor Pharmaceuticals, LLC. The agreement reflects that Supernus is purchasing assets related to the compound and the purchased intellectual property rather than acquiring equity.

The document describes Supernus as a CNS specialty pharmaceutical company with assets in neurology and a late-stage pipeline in psychiatry. It also references a prior Development and Option Agreement dated April 21, 2020, and a May 5, 2025 binding memorandum of understanding in which Supernus exercised an option to license or purchase the product intellectual property and waived an initial acquisition fee.